Bristol-Myers Squibb Company
Explore Bristol-Myers Squibb
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
4 leaders · Full leadership timeline
Bristol Myers Squibb combines a long operating history with a current strategy shaped by FY2025 financial results, leadership priorities, and competitive pressure.
Bristol Myers Squibb makes money through oncology, hematology, immunology, cardiovascular, neuroscience, cell therapy, and radiopharmaceutical medicines. Its model depends on disciplined capital allocation, durable customer or channel relationships, and execution inside markets where scale and trust matter.
Board Chair and Chief Executive Officer
Chris Boerner leads Bristol Myers Squibb as it executes against the priorities reflected in the FY2025 update: Bristol Myers Squibb is using legacy cash flows from Eliquis, Opdivo, and hematology brands to fund a pipeline reset in oncology, neuroscience, immunology, cell therapy, and radiopharmaceuticals.
Chief Executive Officer
Giovanni Caforio led Bristol Myers Squibb through the Celgene acquisition era and is now part of the company's recent CEO history rather than the current CEO entry.
Chief Financial Officer
Schoenhoff has maintained the company's fortress balance sheet and disciplined capital allocation strategy, supporting a $10.5 billion R&D budget while simultaneously funding a $6.0 billion dividend distribution and a continuous share repurchase program in FY2024, demonstrating exceptional financial discipline in a flat-to-declining revenue environment.
Chief Medical Officer
Robertson has been instrumental in driving the strategic pivot toward precision medicine, utilizing the company's advanced data analytics and real-world evidence generation to accelerate clinical trial design and identify novel drug targets in oncology and neuroscience.
The financial markets have consistently evaluated the organization based on its ability to execute its pipeline and manage the patent cliff, a challenge that has defined the strategic narrative of the enterprise for the past decade. The business model's resilience is tested by the inherent risk of the pharmaceutical patent cliff, which is currently manifesting in the severe erosion of Revlimid sales and the impending loss of exclusivity for Eliquis in 2025 and 2026. The competitive narrative is a story of continuous adaptation and innovation, of navigating the challenges and uncertainties of the biopharmaceutical industry, and of using its unique capabilities to deliver value to patients and shareholders. The financial narrative is a story of resilience and adaptability, of navigating the challenges and uncertainties of the biopharmaceutical industry, and of using its unique capabilities to deliver value to patients and shareholders.
While the HTA regulation is intended to simplified the market access process, it also introduces the risk of more stringent pricing and reimbursement decisions, as countries with historically lower drug prices may exert greater influence over the pan-European assessment, potentially leading to lower launch prices and reduced revenue potential for new pharmaceutical products. The high cost of these curative therapies has raised concerns among payers and healthcare systems about their long-term affordability and budget impact, leading to the development of novel payment models, such as annuity payments and outcomes-based contracts, to spread the cost over time and tie reimbursement to actual patient outcomes. Surprisingly, while the organization has been among the leaders of developing these novel payment models, the complexity and administrative burden of managing these contracts pose a significant operational challenge, and the ultimate success of these models in securing broad market access for advanced therapies remains uncertain. The organization is also facing challenges in its supply chain, particularly in the sourcing of raw materials and the manufacturing of complex biologics and radiopharmaceutical isotopes.
Bristol Myers Squibb is known for oncology, hematology, immunology, cardiovascular, neuroscience, cell therapy, and radiopharmaceutical medicines.
Bristol Myers Squibb reported $48.2B in FY2025 revenue.
Chris Boerner is the current CEO of Bristol Myers Squibb.
Bristol Myers Squibb has about 32,500 employees based on the latest annual reporting context.
The biggest risk is patent-cliff execution: generic pressure on legacy brands must be offset by launches such as Cobenfy, Opdivo Qvantig, Reblozyl, Breyanzi, and radiopharmaceutical programs.